At 12 weeks, it significantly enhanced tissue maturation and collagen arrangement in the defect area and mitigated cartilage degeneration. This strategy guides meniscus healing with a dual function by modulating the inflammatory environment while providing biomimetic structural support.

In response to lipopolysaccharide stimulation, both extracts had anti-inflammatory effects like those of the control medication celecoxib, which decreased 5-LOX and TNF-α expression by 0.3554-fold and 0.2263-fold, respectively. Molecular docking highlighted that dihydrosterculic acid showed the tightest fit within 5-LOX center revealing binding energy (∆G = -35.09 kcal/mol). Consequently, this study highlighted the relevance of the flowers of both Ceiba species in treating inflammatory disorders that in turn confirmed the traditional medicinal uses of these plants.

Extract of Terminalia catappa, in combination with aspirin, reduced WBC count but increased platelet indices. This indicates the potential of the extract to reduce inflammation in diabetes mellitus, but with the risk of thrombocytosis.

Here, we design and construct an in situ injectable therapeutic hydrogel encapsulating 1-methyl-d-tryptophan (1-d-MT), a small-molecule competitive inhibitor of indoleamine 2,3-dioxygenase, and meloxicam, a selective inhibitor of cyclooxygenase-2 (Ge1MT/Mel hydrogel) to prevent postoperative tumor metastasis and relapse. Importantly, the Ge1MT/Mel hydrogel markedly stimulates a potent antitumor immune response in the cancer lesion microenvironment, increasing antitumor immune cells including CD8+ T cells, as well as elevating antitumor cytokines such as interferon-γ. Overall, combination immunotherapy via the Ge1MT/Mel hydrogel after surgery represents a promising strategy to minimize residual tumor burden and reduce recurrence risk following tumor resection.

Remarkably, sodium selenite, aflodac, and genistein were commonly predicted by the biomarkers...Ultimately, AKT1 and SHC1 were significantly upregulated in NOA. This study identified 3 biomarkers as being associated with NOA, providing valuable clues to help treat and predict NOA.

Its effects were comparable to COX-2 gene silencing, with a favorable preclinical safety profile supporting long-term clinical use. These findings elucidate the neuroprotective mechanism of celecoxib, propose COX-2/PGE2 as a therapeutic target for CIPN, and lay a foundation for relevant combination therapy research, highlighting celecoxib's potential in CIPN management.

P=N/A, N=40, Recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

The combined therapy also increases the overall efficacy rate, reduces the effecting time, without increasing systemic adverse events. The combined regimen represents an effective and safe treatment option to offer benefits for clinical application.

P3, N=123, Completed, Laboratorios Liomont

P4, N=41, Completed, Stony Brook University | Active, not recruiting --> Completed | Trial primary completion date: Feb 2026 --> Aug 2025